Silverfin false 31/03/2023 01/04/2022 31/03/2023 Dr G Duncan 02/11/2018 Mr S A Duncan 02/11/2018 Mr S Duncan 02/11/2018 Mrs L McCreadie 02/11/2018 24 November 2023 The Principal activity of the Company during the financial year is that of specialists medical practice activities. SC612577 2023-03-31 SC612577 bus:Director1 2023-03-31 SC612577 bus:Director2 2023-03-31 SC612577 bus:Director3 2023-03-31 SC612577 bus:Director4 2023-03-31 SC612577 2022-03-31 SC612577 core:CurrentFinancialInstruments 2023-03-31 SC612577 core:CurrentFinancialInstruments 2022-03-31 SC612577 core:ShareCapital 2023-03-31 SC612577 core:ShareCapital 2022-03-31 SC612577 core:RetainedEarningsAccumulatedLosses 2023-03-31 SC612577 core:RetainedEarningsAccumulatedLosses 2022-03-31 SC612577 core:OtherPropertyPlantEquipment 2022-03-31 SC612577 core:OtherPropertyPlantEquipment 2023-03-31 SC612577 2021-03-31 SC612577 bus:OrdinaryShareClass1 2023-03-31 SC612577 bus:OrdinaryShareClass2 2023-03-31 SC612577 bus:OrdinaryShareClass3 2023-03-31 SC612577 bus:OrdinaryShareClass4 2023-03-31 SC612577 core:KeyManagementPersonnel 2023-03-31 SC612577 core:KeyManagementPersonnel 2022-03-31 SC612577 2022-04-01 2023-03-31 SC612577 bus:FullAccounts 2022-04-01 2023-03-31 SC612577 bus:SmallEntities 2022-04-01 2023-03-31 SC612577 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 SC612577 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 SC612577 bus:Director1 2022-04-01 2023-03-31 SC612577 bus:Director2 2022-04-01 2023-03-31 SC612577 bus:Director3 2022-04-01 2023-03-31 SC612577 bus:Director4 2022-04-01 2023-03-31 SC612577 core:OtherPropertyPlantEquipment 2022-04-01 2023-03-31 SC612577 2021-04-01 2022-03-31 SC612577 bus:OrdinaryShareClass1 2022-04-01 2023-03-31 SC612577 bus:OrdinaryShareClass1 2021-04-01 2022-03-31 SC612577 bus:OrdinaryShareClass2 2022-04-01 2023-03-31 SC612577 bus:OrdinaryShareClass2 2021-04-01 2022-03-31 SC612577 bus:OrdinaryShareClass3 2022-04-01 2023-03-31 SC612577 bus:OrdinaryShareClass3 2021-04-01 2022-03-31 SC612577 bus:OrdinaryShareClass4 2022-04-01 2023-03-31 SC612577 bus:OrdinaryShareClass4 2021-04-01 2022-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: SC612577 (Scotland)

DUNCAN RADIOLOGY SOLUTIONS LTD

UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2023
PAGES FOR FILING WITH THE REGISTRAR

DUNCAN RADIOLOGY SOLUTIONS LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 MARCH 2023

Contents

DUNCAN RADIOLOGY SOLUTIONS LTD

BALANCE SHEET

AS AT 31 MARCH 2023
DUNCAN RADIOLOGY SOLUTIONS LTD

BALANCE SHEET (continued)

AS AT 31 MARCH 2023
Note 2023 2022
£ £
Fixed assets
Tangible assets 3 3,686 3,769
3,686 3,769
Current assets
Debtors 4 1,877 3,064
Cash at bank and in hand 5 6,378 6,064
8,255 9,128
Creditors: amounts falling due within one year 6 ( 5,294) ( 4,265)
Net current assets 2,961 4,863
Total assets less current liabilities 6,647 8,632
Provision for liabilities 7, 8 ( 921) ( 942)
Net assets 5,726 7,690
Capital and reserves
Called-up share capital 9 100 100
Profit and loss account 5,626 7,590
Total shareholders' funds 5,726 7,690

For the financial year ending 31 March 2023 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Duncan Radiology Solutions Ltd (registered number: SC612577) were approved and authorised for issue by the Director on 24 November 2023. They were signed on its behalf by:

Dr G Duncan
Director
DUNCAN RADIOLOGY SOLUTIONS LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 MARCH 2023
DUNCAN RADIOLOGY SOLUTIONS LTD

NOTES TO THE FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 MARCH 2023
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Duncan Radiology Solutions Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in Scotland. The address of the Company's registered office is 66 Tay Street, Perth, PH2 8RA, United Kingdom.

The financial statements have been prepared under the historical cost convention and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Turnover represents amounts receivable for specialist medical practice services.

Revenue is recognised when the company has entitlement to the income in exchange for the provision of services.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. 20 - 33 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Non-financial assets
At each balance sheet date, the company reviews its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include deposits held at call with banks.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Basic financial assets
Basic financial assets, which include debtors and bank balances, are measured at transaction price including transaction costs.

Basic financial liabilities
Basic financial liabilities, including creditors are recognised at transaction price.

Equity instruments
Equity instruments issued by the Company are recorded at the fair value of cash or other resources received or receivable, net of direct issue costs. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the Company.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation.

2. Employees

2023 2022
Number Number
Monthly average number of persons employed by the Company during the year, including directors 4 4

3. Tangible assets

Plant and machinery etc. Total
£ £
Cost
At 01 April 2022 6,844 6,844
Additions 1,612 1,612
Disposals ( 1,119) ( 1,119)
At 31 March 2023 7,337 7,337
Accumulated depreciation
At 01 April 2022 3,075 3,075
Charge for the financial year 1,255 1,255
Disposals ( 679) ( 679)
At 31 March 2023 3,651 3,651
Net book value
At 31 March 2023 3,686 3,686
At 31 March 2022 3,769 3,769

4. Debtors

2023 2022
£ £
Trade debtors 1,540 1,406
Other debtors 337 1,658
1,877 3,064

5. Cash and cash equivalents

2023 2022
£ £
Cash at bank and in hand 6,378 6,064

6. Creditors: amounts falling due within one year

2023 2022
£ £
Corporation tax 3,133 2,463
Other creditors 2,161 1,802
5,294 4,265

7. Provision for liabilities

2023 2022
£ £
Deferred tax 921 942

8. Deferred tax

2023 2022
£ £
At the beginning of financial year ( 942) ( 945)
Credited to the Statement of Income and Retained Earnings 21 3
At the end of financial year ( 921) ( 942)

9. Called-up share capital

2023 2022
£ £
Allotted, called-up and fully-paid
70 A ordinary shares of £ 1.00 each 70 70
10 B ordinary shares of £ 1.00 each 10 10
10 C ordinary shares of £ 1.00 each 10 10
10 D ordinary shares of £ 1.00 each 10 10
100 100

10. Related party transactions

Transactions with the entity’s directors (or members of its governing body)

Amounts owed by directors

2023 2022
£ £
Amounts Owed by Directors 337 1,658

Amounts advanced to the director in the year totals £15,487 . Amounts repaid by the directors in the year totals £16,808. The loan is unsecured and has been repaid within 9 months of the balance sheet date.